JHEP Reports (Jun 2023)

A genomic enhancer signature associates with hepatocellular carcinoma prognosis

  • Ah-Jung Jeon,
  • Chukwuemeka George Anene-Nzelu,
  • Yue-Yang Teo,
  • Shay Lee Chong,
  • Karthik Sekar,
  • Lingyan Wu,
  • Sin-Chi Chew,
  • Jianbin Chen,
  • Raden Indah Kendarsari,
  • Hannah Lai,
  • Wen Huan Ling,
  • Neslihan Arife Kaya,
  • Jia Qi Lim,
  • Alexander Yaw Fui Chung,
  • Peng-Chung Cheow,
  • Juinn Huar Kam,
  • Krishnakumar Madhavan,
  • Alfred Kow,
  • Iyer Shridhar Ganpathi,
  • Tony Kiat Hon Lim,
  • Wei-Qiang Leow,
  • Shihleone Loong,
  • Tracy Jiezhen Loh,
  • Wei Keat Wan,
  • Gwyneth Shook Ting Soon,
  • Yin Huei Pang,
  • Boon Koon Yoong,
  • Diana Bee-Lan Ong,
  • Jasmine Lim,
  • Vanessa H. de Villa,
  • Rouchelle D. dela Cruz,
  • Rawisak Chanwat,
  • Jidapa Thammasiri,
  • Glenn K. Bonney,
  • Brian K.P. Goh,
  • Roger Sik Yin Foo,
  • Pierce Kah-Hoe Chow

Journal volume & issue
Vol. 5, no. 6
p. 100715

Abstract

Read online

Background & Aims: Lifestyle and environmental-related exposures are important risk factors for hepatocellular carcinoma (HCC), suggesting that epigenetic dysregulation significantly underpins HCC. We profiled 30 surgically resected tumours and the matched adjacent normal tissues to understand the aberrant epigenetic events associated with HCC. Methods: We identified tumour differential enhancers and the associated genes by analysing H3K27 acetylation (H3K27ac) chromatin immunoprecipitation sequencing (ChIP-seq) and Hi-C/HiChIP data from the resected tumour samples of 30 patients with early-stage HCC. This epigenome dataset was analysed with previously reported genome and transcriptome data of the overlapping group of patients from the same cohort. We performed patient-specific differential expression testing using multiregion sequencing data to identify genes that undergo both enhancer and gene expression changes. Based on the genes selected, we identified two patient groups and performed a recurrence-free survival analysis. Results: We observed large-scale changes in the enhancer distribution between HCC tumours and the adjacent normal samples. Many of the gain-in-tumour enhancers showed corresponding upregulation of the associated genes and vice versa, but much of the enhancer and gene expression changes were patient-specific. A subset of the upregulated genes was activated in a subgroup of patients’ tumours. Recurrence-free survival analysis revealed that the patients with a more robust upregulation of those genes showed a worse prognosis. Conclusions: We report the genomic enhancer signature associated with differential prognosis in HCC. Findings that cohere with oncofoetal reprogramming in HCC were underpinned by genome-wide enhancer rewiring. Our results present the epigenetic changes in HCC that offer the rational selection of epigenetic-driven gene targets for therapeutic intervention or disease prognostication in HCC. Impact and Implications: Lifestyle and environmental-related exposures are the important risk factors of hepatocellular carcinoma (HCC), suggesting that tumour-associated epigenetic dysregulations may significantly underpin HCC. We profiled tumour tissues and their matched normal from 30 patients with early-stage HCC to study the dysregulated epigenetic changes associated with HCC. By also analysing the patients’ RNA-seq and clinical data, we found the signature genes – with epigenetic and transcriptomic dysregulation – associated with worse prognosis. Our findings suggest that systemic approaches are needed to consider the surrounding cellular environmental and epigenetic changes in HCC tumours.

Keywords